glp 1 agonist news GLP-1 Agonists Weight Loss Drugs Market Report, 2025-2030 Three new studies reveal surprising
Description
Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis"
Here we highlight data informing the safety, efficacy, and potential utility of new and emerging glucagon-like peptide-1 medicines
cytotoxic agents and selected antiepileptic drugs (including valproate, carbamazepine, phenytoin, fosphenytoin, primidone, topiramate and phenobarbital)
